National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Fremanezumab (Ajovy®)

Fremanezumab is indicated for prophylaxis of migraine in adults who have at least four migraine days per month.

 

NCPE Assessment Process Complete
Rapid review commissioned 12/03/2019
Rapid review completed 17/04/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fremanezumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
Full pharmacoeconomic assessment commissioned by HSE 01/05/2019
Pre-submission consultation with Applicant 11/06/2019
Submission received from Applicant 26/09/2019
Preliminary review sent to Applicant 06/12/2019
NCPE assessment re-commenced 10/01/2020
Preliminary review follow-up sent to Applicant 30/01/2020
NCPE assessment re-commenced 12/05/2020
Factual accuracy sent to Applicant 24/07/2020
NCPE assessment re-commenced 31/07/2020
NCPE assessment completed 07/09/2020
NCPE assessment outcome Chronic migraine: The NCPE recommends that fremanezumab (Ajovy®), for the prophylaxis of migraine in adult patients with chronic migraine who have failed three or more migraine-preventive treatments, be considered for reimbursement. *

Episodic migraine: The NCPE recommends that fremanezumab (Ajovy®), for the prophylaxis of migraine in adult patients with episodic migraine who have failed three or more migraine-preventive treatments, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments. *

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.